National
WHO urges global push to treat hepatitis C
Publish Date: Apr 10, 2014
WHO urges global push to treat hepatitis C
Hepatitis C testing kit
  • mail
  • img
newvision

GENEVA - The World Health Organization called Wednesday for a dramatic increase in screening and treatment of hepatitis C, saying higher demand would help drive down the cost of drugs for the disease.

Most of the 185 million people chronically infected with the liver disease worldwide do not know they have it due to lack of screening, and many of those who do cannot access treatment due to the high cost, the UN agency said.

Some 350,000 people die of hepatitis C-related liver diseases annually, and as many as four million people become infected each year, according to the WHO, which on Wednesday released its first-ever guidelines on fighting the disease.

Hepatitis C is caused by a virus that can be transmitted through sharing needles, receiving contaminated blood transfusions or having sex with an infected person.

No vaccine exists for the disease, but new antiviral treatments like Gilead Sciences' Sofosbuvir, recently approved in the United States and the European Union, have been shown to cure more than 90 percent of those treated, up from 50 to 60 percent for the previous generation of drugs.

But with a price tag of $84,000 (61,000 euros) for a 12-week treatment of Sofosbuvir in the United States -- or about $1,000 a tablet -- few can afford it, WHO expert Peter Beyer said.

Producing that drug meanwhile costs only between $68 and $136 per treatment, Beyer said, insisting the market for the drugs needed to be vastly expanded to spur more competition and help shrink the prices.

"We want to benefit from the experience we have with HIV," he said, noting that the cost of drugs used to treat the virus that leads to AIDS had been pushed down from around $10,000 to $100 per person per year.

- 'Power of scaling up' -

However, hepatitis C has a much lower profile in most countries, making it difficult to convince governments to address the disease.

Stefan Wiktor, head of the WHO's Global Hepatitis Programme, pointed to Egypt as an example of how countries can use "the power of scaling up" to push down prices.

Egypt has the world's highest infection rate of hepatitis C at more than 10 percent of the population because syringes are routinely re-used, according to WHO.

The country, which has prioritised tackling the disease and has treated more than 300,000 people, has negotiated a 12-week treatment price of just $900 from Gilead.

WHO expects more new drugs to hit the market soon, which could help bring down prices and broaden access, Wiktor said.

Doctors Without Borders (MSF) meanwhile expressed outrage at the high prices and said even steep discounts to countries like Thailand, which looks set to receive Sofosbuvir treatments for $5,000, were not enough.

"When you're starting from such an exorbitant price in the US, the price Gilead will offer middle-income countries ... may seem like a good discount, but it will still be too expensive for many of these countries to scale up treatment," said Rohit Malpani, of MSF's Access Campaign.

Securing a decent price is only part of the battle though.

Most cases of hepatitis C, which shows no symptoms until a person develops liver damage or cancer, go undetected. In the European Union, only two to three percent of sufferers receive treatment.

"Many people remain unaware, sometimes for decades, that they are infected with hepatitis C," said WHO expert Andrew Ball, calling for anyone at risk of carrying the disease to be screened.

Hepatitis C statistics are sketchy, but WHO says the disease in developing countries like Egypt, or Pakistan, where nearly five percent of the population is infected, is usually contracted in a healthcare setting.

In Europe, the United States and other wealthy nations, intravenous drug use is usually the cause.

Worldwide, 69 percent of drug injectors are infected with the liver disease, according to WHO.

Yet current and former drug users are often denied treatment, Wiktor lamented, insisting on the benefit of treating everyone with chronic hepatitis C.

AFP

The statements, comments, or opinions expressed through the use of New Vision Online are those of their respective authors, who are solely responsible for them, and do not necessarily represent the views held by the staff and management of New Vision Online.

New Vision Online reserves the right to moderate, publish or delete a post without warning or consultation with the author.Find out why we moderate comments. For any questions please contact digital@newvision.co.ug

  • mail
  • img
blog comments powered by Disqus
Also In This Section
Premier hails Uganda’s relations with France, Germany
The Prime Minister, Dr. Ruhakana Rugunda, has applauded the level of trust, co-operation and brotherhood that exist between France, Germany and Uganda....
Reduce fertility rate to boost economic development – experts
The government should put in place effective measures to reduce the runaway fertility rate if it is to reap the benefits of demographic dividend, population experts have warned....
KCCA urged on reforms to protect women and children
Women activists are demanding reforms in the KCCA enforcement policy to ensure the safety of Ugandans – especially women and children – in public spaces....
Uganda, Saudi ties shaky after maid abuse video
A video of a Ugandan maid abusing a child that was uploaded by a diplomat from the Saudi Embassy in Uganda has gone viral....
Kaahwa is Africa agriculture ambassador
At 30 years old, Jean Kaahwa has been farming since he finished university – something most youths can’t imagine doing....
Elderly should take cholesterol-lowering drugs
Nearly everyone aged 66 to 75 should consider taking cholesterol-lowering drugs called statins to reduce their risk of heart attack and stroke....
Should Govt lease parts of Lake Victoria to private developers?
Its Ok
No Way
Not Sure
follow us
subscribe to our news letter